Khan Muhammad Ali, Hammad Tariq, Khan Zubair, Lee Wade, Gaidhane Monica, Tyberg Amy, Kahaleh Michel
Division of Gastroenterology, University of Tennessee Health Science Center, Memphis, TN, USA.
Division of Gastroenterology, Baylor College of Medicine, Houston, TX, USA.
Endosc Int Open. 2018 Apr;6(4):E474-E483. doi: 10.1055/s-0044-102299. Epub 2018 Mar 29.
Symptomatic pancreatic fluid collections (PFCs) are managed by surgical, percutaneous, or endoscopic drainage. Due to morbidity associated with surgical drainage, percutaneous and/or endoscopic options have increasingly been used as initial management.
We conducted a systematic review and meta-analysis comparing the efficacy and safety of endoscopic versus percutaneous drainage for management of PFCs.
We searched several databases from inception through 31 August 2017 to identify comparative studies using endoscopic or percutaneous drainage for PFCs. Our primary outcome was clinical success. Secondary outcomes were technical success, adverse events (AE), rates of recurrence, requirement for subsequent procedures, and length of stay in hospital. Pooled risk ratios (RR) and mean difference (MD) were calculated for categorical and continuous outcomes, respectively.
Seven studies with 490 patients were included in the final analysis. Pooled RR for clinical success was 0.40 (0.26, 0.61), = 42 % in favor of endoscopic management. On sensitivity analysis, after excluding one study on patients with walled-off necrosis (WON), the clinical success was 0.43 (0.28, 0.66) with no heterogeneity. Pooled RR for technical success was 1.50 (0.52, 4.37) with no heterogeneity. Pooled RR for AE and rate of recurrence were 0.77 (0.46, 1.28) and 0.60 (0.29, 1.24), respectively. Pooled MD for length of stay in hospital and rate of re-intervention were - 8.97 (- 12.88, - 5.07) and - 0.66 (- 0.93, - 0.38), respectively, in favor of endoscopic drainage.
Endoscopic drainage should be the preferred therapeutic modality for PFCs compared to percutaneous drainage as it is associated with significantly better clinical success, a lower re-intervention rate, and a shorter hospital length of stay.
有症状的胰腺液体积聚(PFCs)可通过手术、经皮或内镜引流进行处理。由于手术引流存在相关并发症,经皮和/或内镜治疗方案越来越多地被用作初始治疗方法。
我们进行了一项系统评价和荟萃分析,比较内镜引流与经皮引流治疗PFCs的疗效和安全性。
我们检索了从数据库建立至2017年8月31日的多个数据库,以确定使用内镜或经皮引流治疗PFCs的比较研究。我们的主要结局是临床成功。次要结局包括技术成功、不良事件(AE)、复发率、后续手术需求以及住院时间。分别针对分类和连续结局计算合并风险比(RR)和平均差(MD)。
最终分析纳入了7项研究,共490例患者。临床成功的合并RR为0.40(0.26,0.61),内镜治疗的优势比为42%。敏感性分析中,排除一项关于包裹性坏死(WON)患者的研究后,临床成功率为0.43(0.28,0.66),无异质性。技术成功的合并RR为1.50(0.52,4.37),无异质性。AE和复发率的合并RR分别为0.77(0.46,1.28)和0.60(0.29,1.24)。住院时间和再次干预率的合并MD分别为-8.97(-12.88,-5.07)和-0.66(-0.93,-0.38),均有利于内镜引流。
与经皮引流相比,内镜引流应作为PFCs的首选治疗方式,因为它具有显著更好的临床成功率、更低的再次干预率和更短的住院时间。